ZA200809284B - Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders - Google Patents
Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disordersInfo
- Publication number
- ZA200809284B ZA200809284B ZA200809284A ZA200809284A ZA200809284B ZA 200809284 B ZA200809284 B ZA 200809284B ZA 200809284 A ZA200809284 A ZA 200809284A ZA 200809284 A ZA200809284 A ZA 200809284A ZA 200809284 B ZA200809284 B ZA 200809284B
- Authority
- ZA
- South Africa
- Prior art keywords
- isopropoxypyridin
- penten
- amine
- methyl
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74682106P | 2006-05-09 | 2006-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200809284B true ZA200809284B (en) | 2009-08-26 |
Family
ID=38441430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200809284A ZA200809284B (en) | 2006-05-09 | 2008-10-29 | Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders |
Country Status (29)
Country | Link |
---|---|
US (3) | US8461344B2 (fr) |
EP (2) | EP2418201B1 (fr) |
JP (1) | JP4477097B2 (fr) |
KR (1) | KR20090005369A (fr) |
CN (1) | CN101472893A (fr) |
AR (1) | AR060786A1 (fr) |
AU (1) | AU2007249485B2 (fr) |
BR (1) | BRPI0709781A2 (fr) |
CA (1) | CA2649961A1 (fr) |
DK (1) | DK2418201T3 (fr) |
EC (1) | ECSP088876A (fr) |
ES (1) | ES2460919T3 (fr) |
HR (1) | HRP20140385T1 (fr) |
IL (1) | IL194833A0 (fr) |
MX (1) | MX2008013982A (fr) |
MY (1) | MY144132A (fr) |
NO (1) | NO20084567L (fr) |
NZ (1) | NZ597177A (fr) |
PL (1) | PL2418201T3 (fr) |
PT (1) | PT2418201E (fr) |
RS (1) | RS53286B (fr) |
RU (1) | RU2440984C2 (fr) |
SA (1) | SA07280230B1 (fr) |
SI (1) | SI2418201T1 (fr) |
TW (1) | TWI389889B (fr) |
UA (1) | UA96447C2 (fr) |
UY (1) | UY30330A1 (fr) |
WO (1) | WO2007134034A1 (fr) |
ZA (1) | ZA200809284B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
US8017785B2 (en) * | 2006-05-09 | 2011-09-13 | Astrazeneca Ab | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine |
US20080085888A1 (en) * | 2006-09-15 | 2008-04-10 | Breining Scott R | Therapeutic Combinations |
US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
CN101772343A (zh) * | 2007-07-31 | 2010-07-07 | 塔格赛普有限公司 | (2s)-(4e)-n-甲基-5-(3-(5-异丙氧基吡啶)基)-4-戊烯-2-胺的经皮给药 |
WO2009151394A1 (fr) * | 2008-06-11 | 2009-12-17 | Astrazeneca Ab | Compositions sublinguales contenant un (2s)-(4e)-n-méthyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine |
WO2010080757A2 (fr) * | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinaisons avec un agoniste alpha-4-bêta-2 nicotinique |
FR2959107B1 (fr) | 2010-04-23 | 2015-03-27 | Oreal | Unite d'application d'un produit cosmetique |
SG185497A1 (en) * | 2010-05-20 | 2012-12-28 | Astrazeneca Ab | New process for the preparation of aryl substituted olefinic amines |
WO2013184732A1 (fr) * | 2012-06-06 | 2013-12-12 | Targacept, Inc. | 1,5-naphthalènedisulfonate de (2s)-(4e)-n-méthyl-5-[3-(5-isopropoxypyridin)yl]-4-pentèn-2-amine cristallin |
KR101579904B1 (ko) | 2014-09-05 | 2016-01-05 | 동신대학교산학협력단 | 마스카라 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4192946A (en) * | 1978-06-29 | 1980-03-11 | Ciba-Geigy Corporation | Process for producing 3-hydroxy-5-halopyridines |
DE3148651A1 (de) * | 1981-12-09 | 1983-07-21 | Henkel Kgaa | "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente" |
US4582823A (en) * | 1984-08-15 | 1986-04-15 | Warner-Lambert Company | Method for treating schizophrenia and medicaments therefor |
WO1989000158A1 (fr) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Acides et esters carboxyliques de quinolone de diazabicycloalkyle shunte |
IT1226727B (it) * | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
DE69016688T2 (de) * | 1989-04-20 | 1995-10-05 | Zambon Spa | Dopamin-Medikament-Vorstufe. |
US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
AU9171791A (en) | 1990-12-27 | 1992-08-17 | Abbott Laboratories | N-protected aminoalkylaldehydes |
EP0516409B1 (fr) | 1991-05-30 | 1996-09-11 | MITSUI TOATSU CHEMICALS, Inc. | Composé de tétravinylpyrazine, méthode de préparation et élément électroluminescent et matériau optique non-linéaire d'utilisant |
US5212188A (en) * | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
IT1274018B (it) * | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
CA2192975C (fr) | 1994-06-14 | 1999-09-21 | Anton F. Fliri | Derives de la benzimidazolone a activite dopaminergique centrale |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
DK0900200T5 (da) * | 1996-04-23 | 2010-01-11 | Targacept Inc | Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet |
US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
US20020052497A1 (en) * | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
US5811442A (en) * | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
WO1998050367A1 (fr) | 1997-05-08 | 1998-11-12 | Pfizer Products Inc. | Procedes et produits intermediaires pour la preparation de derives d'indazole substitues |
PL203140B1 (pl) | 1997-10-27 | 2009-08-31 | Neurosearch As | Pochodna homopiperazyny, kompozycja farmaceutyczna zawierająca te pochodne i zastosowanie tej pochodnej |
US6632823B1 (en) * | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
CA2677519A1 (fr) | 1998-06-16 | 1999-12-23 | Targacept, Inc. | Amines olefiniques a substitution aryle et leur utilisation comme agonistes de recepteurs cholinergiques |
US6232316B1 (en) * | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
US6337351B1 (en) | 1998-10-22 | 2002-01-08 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
EP1185514A1 (fr) | 1999-06-07 | 2002-03-13 | Targacept, Inc. | Compositions pharmaceutiques et methodes d'utilisation |
GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
US6506769B2 (en) * | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
AU2001252350A1 (en) | 2000-04-13 | 2001-10-30 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
US6432954B1 (en) * | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6743812B1 (en) | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
EP1379239B1 (fr) | 2001-03-29 | 2007-09-12 | Eli Lilly And Company | N-(2-arylethyl)benzylamines utilisees en tant qu'antagonistes du recepteur 5-ht6 |
GB2381750A (en) * | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
CA2470567A1 (fr) | 2001-12-14 | 2003-06-26 | Targacept, Inc. | Procedes et compositions pour le traitement de troubles du systeme nerveux central |
JP2006512280A (ja) | 2002-03-27 | 2006-04-13 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
US20040044023A1 (en) * | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
JP2007516275A (ja) | 2003-12-23 | 2007-06-21 | ファイザー・プロダクツ・インク | 認知増強および精神病性障害のための治療的組合せ |
US20050171088A1 (en) | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
AU2004319105A1 (en) | 2004-03-29 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
JP4148199B2 (ja) | 2004-07-30 | 2008-09-10 | 松下電工株式会社 | 電気かみそり |
WO2006015299A2 (fr) * | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Dispositif multi-reservoir pour la delivrance de medicament transdermique et la detection |
US7780981B2 (en) * | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US7459469B2 (en) * | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
UA88792C2 (ru) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
US8017785B2 (en) | 2006-05-09 | 2011-09-13 | Astrazeneca Ab | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine |
EP2032149A4 (fr) | 2006-06-13 | 2010-09-01 | Fmc Biopolymer As | Procédé et systèmes d'utilisation de billes et d'hydrogels à base de biopolymères |
US20080085888A1 (en) * | 2006-09-15 | 2008-04-10 | Breining Scott R | Therapeutic Combinations |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US20100028447A1 (en) | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
-
2007
- 2007-04-27 TW TW096115162A patent/TWI389889B/zh not_active IP Right Cessation
- 2007-05-07 AR ARP070101972A patent/AR060786A1/es not_active Application Discontinuation
- 2007-05-07 UY UY30330A patent/UY30330A1/es not_active Application Discontinuation
- 2007-05-08 AU AU2007249485A patent/AU2007249485B2/en not_active Ceased
- 2007-05-08 EP EP11167528.6A patent/EP2418201B1/fr active Active
- 2007-05-08 JP JP2009503340A patent/JP4477097B2/ja not_active Expired - Fee Related
- 2007-05-08 PT PT111675286T patent/PT2418201E/pt unknown
- 2007-05-08 WO PCT/US2007/068446 patent/WO2007134034A1/fr active Application Filing
- 2007-05-08 KR KR1020087027218A patent/KR20090005369A/ko active IP Right Grant
- 2007-05-08 BR BRPI0709781-6A patent/BRPI0709781A2/pt not_active IP Right Cessation
- 2007-05-08 SI SI200731433T patent/SI2418201T1/sl unknown
- 2007-05-08 US US11/745,682 patent/US8461344B2/en not_active Expired - Fee Related
- 2007-05-08 MX MX2008013982A patent/MX2008013982A/es active IP Right Grant
- 2007-05-08 MY MYPI20084443A patent/MY144132A/en unknown
- 2007-05-08 CA CA002649961A patent/CA2649961A1/fr not_active Abandoned
- 2007-05-08 PL PL11167528T patent/PL2418201T3/pl unknown
- 2007-05-08 ES ES11167528.6T patent/ES2460919T3/es active Active
- 2007-05-08 DK DK11167528.6T patent/DK2418201T3/da active
- 2007-05-08 RS RS20140212A patent/RS53286B/en unknown
- 2007-05-08 NZ NZ597177A patent/NZ597177A/xx not_active IP Right Cessation
- 2007-05-08 RU RU2008148325/04A patent/RU2440984C2/ru not_active IP Right Cessation
- 2007-05-08 CN CNA2007800168072A patent/CN101472893A/zh active Pending
- 2007-05-08 SA SA07280230A patent/SA07280230B1/ar unknown
- 2007-05-08 EP EP07783431A patent/EP2021326A1/fr not_active Withdrawn
- 2007-08-05 UA UAA200814135A patent/UA96447C2/ru unknown
-
2008
- 2008-10-22 IL IL194833A patent/IL194833A0/en unknown
- 2008-10-29 ZA ZA200809284A patent/ZA200809284B/xx unknown
- 2008-10-30 NO NO20084567A patent/NO20084567L/no not_active Application Discontinuation
- 2008-11-07 EC EC2008008876A patent/ECSP088876A/es unknown
-
2009
- 2009-10-29 US US12/608,450 patent/US20100048643A1/en not_active Abandoned
-
2013
- 2013-05-14 US US13/893,408 patent/US20130310425A1/en not_active Abandoned
-
2014
- 2014-04-28 HR HRP20140385TT patent/HRP20140385T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200809284B (en) | Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders | |
EP1981526A4 (fr) | L'adiponectine pour le traitement de divers troubles | |
IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
EP1976377A4 (fr) | Composés destinés au traitement des troubles du métabolisme | |
IL178648A0 (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
EP1983972A4 (fr) | Composes pour le traitement de troubles du metabolisme | |
EP2083857A4 (fr) | Procédés pour traiter des troubles en rapport avec le mica | |
ZA200808963B (en) | Compounds for the treatment of metabolic disorders | |
IL192636A0 (en) | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer's disease via gaba receptors | |
ZA200903889B (en) | Process for the synthesis of moxifloxacin hydrochloride | |
PL1824384T3 (pl) | System do diagnostyki zaburzeń pnia mózgu | |
PL1993589T3 (pl) | Sposoby leczenia chorób neurologicznych | |
ZA200805645B (en) | Compounds for the treatment of metabolic disorders | |
PL1841433T3 (pl) | Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego | |
ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
IL189524A0 (en) | Imidazole compounds for the treatment of neurological disorders | |
IL192851A0 (en) | Compounds for the treatment of metabolic disorders | |
IL195392A0 (en) | Compounds for the treatment of metabolic disorders | |
PL1982178T3 (pl) | Sposoby leczenia zaburzeń afektywnych | |
HK1129112A1 (en) | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | |
IL198967A0 (en) | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | |
ZA200807678B (en) | Meridamycin analogues for the treatment of neurodegenerative disorders | |
GB0604772D0 (en) | Use of substituted amine compounds for the treatment of food related disorders | |
IL192982A0 (en) | Compounds for the treatment of metabolic disorders |